Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) FCF Margin (2016 - 2025)

Historic FCF Margin for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to 626.21%.

  • Seres Therapeutics' FCF Margin changed N/A to 626.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 6657.55%, marking a year-over-year increase of 2408315100.0%. This contributed to the annual value of 99.21% for FY2023, which is 32486700.0% up from last year.
  • As of Q3 2025, Seres Therapeutics' FCF Margin stood at 626.21%.
  • Over the past 5 years, Seres Therapeutics' FCF Margin peaked at 626.21% during Q3 2025, and registered a low of 75587.5% during Q4 2023.
  • Its 4-year average for FCF Margin is 9885.75%, with a median of 1766.23% in 2022.
  • The largest annual percentage gain for Seres Therapeutics' FCF Margin in the last 5 years was 43324500bps (2023), contrasted with its biggest fall of -698077100bps (2023).
  • Quarter analysis of 4 years shows Seres Therapeutics' FCF Margin stood at 740.08% in 2021, then tumbled by -681bps to 5779.79% in 2022, then plummeted by -1208bps to 75587.5% in 2023, then soared by 101bps to 626.21% in 2025.
  • Its FCF Margin was 626.21% in Q3 2025, compared to 75587.5% in Q4 2023 and 19694.19% in Q3 2023.